115.47
-3.17
(-2.67%)
As of 3:02:13 PM EST. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 2 | 7 | 5 |
| Avg. Estimate | 1.19 | 1.34 | 5.66 | 6.14 |
| Low Estimate | 1.05 | 1.25 | 5.5 | 6.05 |
| High Estimate | 1.35 | 1.42 | 5.79 | 6.25 |
| Year Ago EPS | 1.38 | 1.2 | 6.09 | 5.66 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 2 | 7 | 7 |
| Avg. Estimate | 39.03M | 36.01M | 163.37M | 188.77M |
| Low Estimate | 37.4M | 31.63M | 161.7M | 168.72M |
| High Estimate | 40.52M | 40.4M | 164.84M | 195M |
| Year Ago Sales | 28.1M | 30.98M | 131.31M | 163.37M |
| Sales Growth (year/est) | 38.88% | 16.26% | 24.41% | 15.55% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | 0.66 | 0.83 | 1.06 | 1.35 |
| EPS Actual | 1.38 | 1.2 | 1.4 | 1.84 |
| Difference | 0.72 | 0.37 | 0.34 | 0.49 |
| Surprise % | 108.85% | 43.88% | 32.55% | 36.66% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.19 | 1.34 | 5.66 | 6.14 |
| 7 Days Ago | 1.18 | 1.22 | 5.64 | 6.16 |
| 30 Days Ago | 1.18 | 1.22 | 5.65 | 6.03 |
| 60 Days Ago | 1.42 | 1.38 | 5.37 | 6.18 |
| 90 Days Ago | 1.44 | 1.21 | 5.39 | 6.25 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 3 |
| Up Last 30 Days | 1 | 1 | 1 | 3 |
| Down Last 7 Days | -- | 1 | -- | 1 |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| LGND | -13.76% | 11.33% | -7.13% | 8.51% |
| S&P 500 | 9.91% | 10.33% | 14.01% | 13.75% |
Upgrades & Downgrades
| Reiterates | Benchmark: Buy to Buy | 12/23/2024 |
| Maintains | Barclays: Overweight to Overweight | 12/16/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 12/11/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/11/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 11/12/2024 |
| Maintains | Benchmark: Buy to Buy | 11/8/2024 |
Related Tickers
OABI OmniAb, Inc.
3.1800
-0.93%
HALO Halozyme Therapeutics, Inc.
56.64
+0.39%
MIRM Mirum Pharmaceuticals, Inc.
48.57
+0.27%
TVTX Travere Therapeutics, Inc.
20.38
-3.20%
VRNA Verona Pharma plc
56.80
-0.77%
INCY Incyte Corporation
74.39
+0.84%
IONS Ionis Pharmaceuticals, Inc.
31.93
-4.17%
PTCT PTC Therapeutics, Inc.
45.75
-0.87%
RARE Ultragenyx Pharmaceutical Inc.
43.03
-0.85%
BMRN BioMarin Pharmaceutical Inc.
63.43
-0.71%